Single Dose Of China S Ad5 Ncov Covid 19 Vaccine Is Safe And Effective In Phase 3 Trial
The Ad5-nCoV vaccine, developed in China, is 57.5% effective against symptomatic COVID-19 infection and 91.7% effective against severe COVID-19 beginning 28 days post-vaccination, according to a phase 3 randomized control trial analysis.No vaccine-related serious adverse events were reported, and most adverse events, including injection-site pain, headache, drowsiness, and generalized muscle aches, were mild to moderate.Research is ongoing to determine the vaccine’s long-term safety and effectiveness as well as its effectiveness against delta, omicron and other variants of concern....